{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:49:26Z","timestamp":1764402566762},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1093\/ejcts\/ezt002","type":"journal-article","created":{"date-parts":[[2013,2,20]],"date-time":"2013-02-20T05:48:04Z","timestamp":1361339284000},"page":"309-315","source":"Crossref","is-referenced-by-count":6,"title":["Mechanical heart valve recipients: anticoagulation in patients with genetic variations of phenprocoumon metabolism\u2020"],"prefix":"10.1093","volume":"44","author":[{"given":"Kerstin","family":"Brehm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Schack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Heilmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Blanke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Joachim","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedhelm","family":"Beyersdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,2,19]]},"reference":[{"key":"key\n\t\t\t\t20170621111839_EZT002C1","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1160\/TH07-07-0454","article-title":"Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles","volume":"98","author":"Oldenburg","year":"2007","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170621111839_EZT002C2","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.287.13.1690","article-title":"Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy","volume":"287","author":"Higashi","year":"2002","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170621111839_EZT002C3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00008571-200401000-00003","article-title":"The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon","volume":"14","author":"Visser","year":"2004","journal-title":"Pharmacogenetics"},{"key":"key\n\t\t\t\t20170621111839_EZT002C4","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1371\/journal.pmed.0020312","article-title":"A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk","volume":"2","author":"Reitsma","year":"2005","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t20170621111839_EZT002C5","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa044503","article-title":"Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose","volume":"352","author":"Rieder","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170621111839_EZT002C6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00008571-199608000-00007","article-title":"The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism","volume":"6","author":"Sullivan-Klose","year":"1996","journal-title":"Pharmacogenetics"},{"key":"key\n\t\t\t\t20170621111839_EZT002C7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.clpt.2006.04.010","article-title":"VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients","volume":"80","author":"Obayashi","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20170621111839_EZT002C8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00008571-200204000-00010","article-title":"Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data","volume":"12","author":"Lee","year":"2002","journal-title":"Pharmacogenetics"},{"key":"key\n\t\t\t\t20170621111839_EZT002C9","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2008-04-149070","article-title":"The largest prospective warfarin-treated cohort supports genetic forecasting","volume":"113","author":"Wadelius","year":"2009","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170621111839_EZT002C10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00228-010-0950-y","article-title":"Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters","volume":"67","author":"Geisen","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20170621111839_EZT002C11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.clpt.6100036","article-title":"VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement","volume":"81","author":"Schalekamp","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20170621111839_EZT002C12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00228-003-0580-8","article-title":"Determination of bleeding risk using genetic markers in patients taking phenprocoumon","volume":"59","author":"Hummers-Pradier","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20170621111839_EZT002C13","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/asheducation-2006.1.467","article-title":"Pharmacogenetics-based coumarin therapy","author":"Gage","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"key\n\t\t\t\t20170621111839_EZT002C14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00228-004-0740-5","article-title":"Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro","volume":"60","author":"Ufer","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20170621111839_EZT002C15","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1160\/TH08-09-0626","article-title":"Subtherapeutic oral anticoagulant therapy: frequency and risk factors","volume":"101","author":"Rombouts","year":"2009","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170621111839_EZT002C16","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1161\/CIRCULATIONAHA.111.070920","article-title":"A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II)","volume":"125","author":"Anderson","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170621111839_EZT002C17","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1093\/eurheartj\/ehr116","article-title":"Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data","volume":"32","author":"van Schie","year":"2011","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170621111839_EZT002C18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1160\/TH03-12-0741","article-title":"The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon","volume":"92","author":"Visser","year":"2004","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170621111839_EZT002C19","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2217\/14622416.9.10.1445","article-title":"VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans","volume":"9","author":"Limdi","year":"2008","journal-title":"Pharmacogenomics"},{"key":"key\n\t\t\t\t20170621111839_EZT002C20","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s11239-012-0740-8","article-title":"Oral anticoagulation and VKORC1 polymorphism in patients with a mechanical heart prosthesis: a 6-year follow-up","volume":"34","author":"Giansante","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"key\n\t\t\t\t20170621111839_EZT002C21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.clpt.2004.08.006","article-title":"Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status","volume":"76","author":"Schalekamp","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20170621111839_EZT002C22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1160\/TH10-03-0194","article-title":"Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy","volume":"105","author":"Luxembourg","year":"2011","journal-title":"Thromb Haemost"}],"container-title":["European Journal of Cardio-Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ejcts\/article-pdf\/44\/2\/309\/17765761\/ezt002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T23:02:04Z","timestamp":1562713324000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejcts\/article-lookup\/doi\/10.1093\/ejcts\/ezt002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,19]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,2,19]]},"published-print":{"date-parts":[[2013,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ejcts\/ezt002","relation":{},"ISSN":["1873-734X","1010-7940"],"issn-type":[{"value":"1873-734X","type":"electronic"},{"value":"1010-7940","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2,19]]}}}